About Us
Liansheng Medtech is a Shanghai‑based, exclusive global distributor and the single point of contact for all overseas hospitals, distributors, and healthcare partners of the HY2900 HIFU system.
HY2900 HIFU system is developed and manufactured by Wuxi Haiying Medical Technology Co., Ltd(无锡海鹰医疗科技股份有限公司), a specialist in focused ultrasound technology.As the authorized international trade partner, LIANSHENG MEDTECH handles all export operations and provides direct support to international buyers seeking access to the HY2900 system.
Liansheng Medtech is partly owned by Chance Non-invasive (辰时无创), China's first dedicated operator of HIFU-based non-invasive treatment centers and a recognized leader in non-invasive gynecological care.
Through this partnership, Liansheng Medtech's international clients benefit not only from the device itself, but from the clinical expertise, real-world case data, and operational know-how developed across Chance's growing network of centers nationwide.
Chance Non-invasive is China's pioneering operator in high-intensity focused ultrasound (HIFU) non-invasive diagnostics and treatment services, with over 10 active centers across 7 provinces and a mission to redefine what non-invasive care can look like.
At the core of Chance's model is a belief that true healthcare goes beyond treating disease — it means protecting the organ, preserving function, and respecting the patient. This drives the "Chance Non-invasive+" brand, integrating HIFU with a full-cycle care pathway covering screening, diagnosis, treatment, and follow-up.
Chance has built a proprietary AI-enabled platform for uterine fibroids, adenomyosis, and other gynecological indications — connecting clinical data, physician systems, and operational infrastructure into one standardized, fully digital care model.
The clinical focus is clear: uterine fibroids affect an estimated 20–40% of women of reproductive age in China — approximately 100 million women — with 1.5 million hysterectomies performed annually. Chance Non-invasive exists to change that.
By partnering with Liansheng Medtech, Chance's clinical model and operational standards are now accessible to international markets through the HY2900 platform.
